Key Financial’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.82K Hold
34
– – ﹤0.01% 1001
2026
Q2
$5.73K Hold
34
– – ﹤0.01% 991
2026
Q1
$4.48K Hold
34
– – ﹤0.01% 1053
2025
Q4
$4.82K Hold
34
– – ﹤0.01% 1040
2025
Q3
$4.66K Hold
34
– – ﹤0.01% 1056
2025
Q2
$4.27K Hold
34
– – ﹤0.01% 1068
2025
Q1
$3.76K Hold
34
– – ﹤0.01% 1056
2024
Q4
$4.64K Hold
34
– – ﹤0.01% 1014
2024
Q3
$3.92K Hold
34
– – ﹤0.01% 1024
2024
Q2
$4.68K Hold
34
– – ﹤0.01% 974
2024
Q1
$4.69K Hold
34
– – ﹤0.01% 956
2023
Q4
$4.48K Hold
34
– – ﹤0.01% 964
2023
Q3
$3.82K Hold
34
– – ﹤0.01% 1003
2023
Q2
$3.21K Buy
+34
New +$3.32K ﹤0.01% 1094

Other funds holding NBIX

Key Financial's NBIX Position: Q3 2026 in Review

Key Financial held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 34 shares worth $4.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Key Financial first reported a position in NBIX in Q2 2023 and has held it in 14 quarters since. The position peaked at $5.73K in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Key Financial held 34 shares of Neurocrine Biosciences worth $4.82K as of Q3 2026.
  • Key Financial left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Key Financial's portfolio in Q3 2026, its #1001 holding.
  • Key Financial first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 14 quarters since.
  • Key Financial's Neurocrine Biosciences position peaked at $5.73K in Q2 2026.
  • 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.